Cellular engineering for therapeutic protein production: product quality, host modification, and process improvement
The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Recombinant proteins offer many therapeutic advantages unavailable in traditional small molecule drugs, but the need for cellular versus chemical synthesis complicates production. Avenues for producing therapeutic biologics are continuously expanding, and developments in biochemistry, cell biology, and bioengineering fuel new discoveries that promise safer, more efficient, and cheaper drugs for consumers. Numerous approaches to express recombinant proteins exist, but Escherichia coli, Saccharomyces cerevisiae, and mammalian systems (e.g. Chinese hamster ovary cells, CHO) are the most widely utilized. Improvements to production in these hosts have focused on novel expression cassettes, cell line modifications, engineering secretion pathways, and media design. Here, we describe recent developments for improving protein production in E. coli, S. cerevisiae, and CHO systems and compare recent advancements to previous knowledge in the field. With the expanding importance and prevalence of protein therapeutics, these improvements will serve as the framework for future discoveries.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Protein Therapeutics: A Summary and Pharmacological Classification
Leader, B., Baca, Q. J., & Golan, D. E. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2399 · Cited by 2,161 · cited 1×
“Escherichia coli, transformed with recombinant human DNA, was used to express insulin, which was isolated, refolded, and purified [2].”
MethodFermented beverages of pre- and proto-historic China
McGovern, P. E., Zhang, J., Tang, J., Zhang, Z., Hall, G. R., Moreau, R. A., Nuñez, A., Butrym, E. D., Richards, M. P., Wang, C.-S., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0407921102 · Cited by 1,091 · cited 1×
“Yeast strains, found naturally in honey or on grape surfaces, fermented the first alcoholic beverages as early as 7000 BC [42].”
BackgroundYamane‐Ohnuki, N., Kinoshita, S., Inoue‐Urakubo, M., Kusunoki, M., Iida, S., Nakano, R., Wakitani, M., Niwa, R., Sakurada, M., Uchida, K., et al. (2004) · Biotechnology and Bioengineering · doi:10.1002/bit.20151 · Cited by 572
HeLa cells 50 years on: the good, the bad and the ugly
Masters, J. R. (2002) · Nature Reviews Cancer · doi:10.1038/nrc775 · Cited by 560
Recombinant protein secretion in Escherichia coli
Mergulhão, F. J. M., Summers, D. K., & Monteiro, G. A. (2005) · Biotechnology Advances · doi:10.1016/j.biotechadv.2004.11.003 · Cited by 485
Laboratory evolution of copper tolerant yeast strains
Adamo, G. M., Brocca, S., Passolunghi, S., Salvato, B., & Lotti, M. (2012) · Microbial Cell Factories · doi:10.1186/1475-2859-11-1 · Cited by 392
One-step generation of triple knockout CHO cell lines using CRISPR/Cas9 and fluorescent enrichment
Grav, L. M., Lee, J. S., Gerling, S., Kallehauge, T. B., Hansen, A. H., Kol, S., Lee, G. M., Pedersen, L. E., & Kildegaard, H. F. (2015) · Biotechnology Journal · doi:10.1002/biot.201500027 · Cited by 131 · cited 2×
“However, in contrast to the lengthy ZFN selection, Kildegaard and coworkers accomplished a single-step triple gene knockout of FUT8, BAX, and BAK with CRISPR/Cas9 in three days, generating a robust protein expression cell line, without any observed offtarget effects related to gene disruption [90].”
BackgroundEfficient expression of full-length antibodies in the cytoplasm of engineered bacteria
Robinson, M.-P., Ke, N., Lobstein, J., Peterson, C., Szkodny, A., Mansell, T. J., Tuckey, C., Riggs, P. D., Colussi, P. A., Noren, C. J., et al. (2015) · Nature Communications · doi:10.1038/ncomms9072 · Cited by 131 · cited 2×
“coli-produced, full-length antibodies have yet reached FDA approval [7].”
BackgroundGarcia-Ortega, X., Ferrer, P., Montesinos, J. L., & Valero, F. (2013) · Biochemical Engineering Journal · doi:10.1016/j.bej.2013.07.013 · Cited by 79 · cited 1×
“pastoris can utilize both glycerol and glucose during growth, and Garcia-Ortega and colleagues (2013) obtained 30% higher yields of Fab (~24 mg/L versus ~18 mg/L) when using glycerol instead of glucose during a fed-batch culture and a PGAP promoter [58].”
Method
Cited by
Pereira, S., Kildegaard, H. F., & Andersen, M. R. (2018) · Biotechnology Journal · doi:10.1002/biot.201700499 · Cited by 214
“The main advantages of using CHO cells compared to other microbial or mammalian cells [4] include the ability of these cells to perform post-translational modifications similar to those found in human proteins, such as glycosylation, which is considered to be a critical quality attribute.”
BackgroundHa, T. K., Hansen, A. H., Kol, S., Kildegaard, H. F., & Lee, G. M. (2018) · Biotechnology Journal · doi:10.1002/biot.201700425 · Cited by 40
“Over the past two decades, the growing demand for therapeutic mAbs has provided a challenge for the process of developing mass production of high quality mAbs [3].”
BackgroundHigh level in vivo mucin-type glycosylation in Escherichia coli
Mueller, P., Gauttam, R., Raab, N., Handrick, R., Wahl, C., Leptihn, S., Zorn, M., Kussmaul, M., Scheffold, M., Eikmanns, B., et al. (2018) · Microbial Cell Factories · doi:10.1186/s12934-018-1013-9 · Cited by 22
Metadata
- Authors
- Wells, E., & Robinson, A. S.
- Venue
- Biotechnology Journal
- Publisher
- Wiley
- Published
- 2016-12-09
- Volume
- 12
- Issue
- 1
- ISSN
- 1860-6768 (ISSN-L)
- 1860-7314
- OpenAlex
- W2560577001
- Cited by
- 83
- References
- 9
- FWCI
- 6.32
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.